Login to Your Account

Mesoblast's MPC Cell Therapy Neofuse Heading to Phase III

By Nuala Moran
Staff Writer

Wednesday, January 16, 2013
LONDON – Mesoblast Ltd. is preparing to discuss plans for Phase III development with regulators and weighing the partnering strategy after reporting positive Phase II results for its Neofuse cell therapy for treating degenerative disc disease by lumber spinal fusion.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription